Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip and Microfluidics: Emerging Themes, Technologies and Applications "Track A"

Michael Heller's Biography



Michael Heller, Professor, Dept Bioengineering, University of California-San Diego

Michael J. Heller received his PhD in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. From 1976 to 1984 he was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) During that time he carried out early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production, and developed some of the first fluorescent resonant energy transfer (FRET) and chemiluminescent oligonucleotide probes for DNA hybridization analysis. He also oversaw Amoco’s sponsored energy and chemical research work at Cetus Corporation, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987. He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989. He was a co-found of Nanogen and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for clinical diagnostic genotyping applications. Dr. Heller is a Professor (Recall/Emeritus) in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He is also now a Distinguished Scientist at the Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR), in Portland, Oregon. He has also co-founded a company called Biological Dynamics which is developing new sample to answer cancer diagnostics technology, based on the novel dielectrophoretic (DEP) technology developed at his UCSD lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology, with particular expertise in the areas of DNA probe diagnostics, electrokinetic lab-on-a-chip devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanostructures. Dr. Heller has over 100 publications and 56 issued US patents.

Michael Heller Image

Integrated Isolation, Detection and Analysis of cf-DNA and Exosome Biomarkers from Cancer Patient Blood Samples - The Road to POC Liquid Biopsy Diagnostics

Monday, 1 October 2018 at 17:30

Add to Calendar ▼2018-10-01 17:30:002018-10-01 18:30:00Europe/LondonIntegrated Isolation, Detection and Analysis of cf-DNA and Exosome Biomarkers from Cancer Patient Blood Samples - The Road to POC Liquid Biopsy DiagnosticsSELECTBIOenquiries@selectbiosciences.com

New AC electrokinetic (ACE) microarray/chip device allows 15-20-minute isolation of cancer related cf-DNA, exosomal RNA and protein biomarkers directly from 20-50ul of patient blood, plasma or serum. Cf-DNA levels can be immediately determined directly on the chip (in-situ) using DNA specific dyes and then immunofluorescent analysis can be carried out to identify exosomal protein biomarkers. Presently, cf-DNA and exosomal RNA are then eluted from the ACE chip, and PCR and sequencing analysis carried out to identify the cancer-related point mutations. New procedures are now being developed to carry out on-chip PCR for DNA/RNA analysis. On-chip integration of proteomic and genomic analysis is a major step forward in the quest for seamless sample to answer POC liquid biopsy diagnostics.


Add to Calendar ▼2018-10-01 00:00:002018-10-03 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics: Emerging Themes, Technologies and Applications "Track A"SELECTBIOenquiries@selectbiosciences.com